Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

FDA Approves Nilotinib for Frontline and Secondline Use in Pediatric CML

The FDA approved nilotinib for first- and secondline use in pediatric patients (≥1 year) with Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CP-CML). Approval was...

National Academy of Medicine Launches Resource Center Addressing Physician Burnout

The National Academy of Medicine (NAM) launched the Clinician Well-Being Knowledge Hub, a comprehensive repository housing resources to combat physician burnout. The Knowledge Hub...

CMS Decides Coverage Requirements for NGS-Based Testing

CMS released a National Coverage Determination (NCD) on next-generation sequencing (NGS) for Medicare beneficiaries with advanced cancer. The agency determined that NGS as a...

Ivosidenib Receives Priority Review for the Treatment of Relapsed/Refractory AML

The FDA granted priority review to ivosidenib for the treatment of relapsed/refractory IDH1-mutated AML. The decision was based on results from an ongoing, single-arm,...

FDA Expands Treatment Window for Blood Clot Retrieval Device

The FDA cleared the use of the Trevo clot retrieval device to treat certain stroke patients up to 24 hours after symptom onset –...

Report: U.S. Health-Care Spending Projections Increase Year Over Year

A new report from the U.S. Centers for Medicare and Medicaid Services (CMS) projects that health-care spending will increase 5.3 percent in 2018 –...

NIH Funding Tied to FDA Approval of 210 Drugs Since 2010

A report published in Proceedings of the National Academy of Sciences found that funding from the National Institutes of Health (NIH) contributed to published...

ASCO Updates Platelet Transfusion Guidelines for Patients With Cancer

ASCO Updates Platelet Transfusion Guidelines for Patients With Cancer Adult patients undergoing hematopoietic cell transplantation (HCT) can safely delay platelet transfusion until the first sign...

Brentuximab Vedotin Approved for Classical Hodgkin Lymphoma

The FDA expanded the approval of brentuximab vedotin to include the treatment of adult patients with previously untreated stage III or IV classical Hodgkin...

FDA Examining Patient Deaths Associated With Extracorporeal Photopheresis Treatment

The FDA published a letter to health-care providers noting that the CELLEX® Photopheresis System is under review following reports of venous thromboembolism (VTE), including...
Advertisement

Current Issue

May 2018, Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.